Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Pivotal phase II/III MS trial of MBP-8298 recommended to continue

Feb. 10, 2006

New Abilify options now available

Feb. 9, 2006

MC4 antagonist/serotonin transport inhibitor for stress-related anxiety and depression

Feb. 9, 2006

PBT-2 completes phase I program

Feb. 9, 2006

TRO-19622 completes phase I trials

Feb. 9, 2006

IND cleared for phase I study of Tramadol ER

Feb. 9, 2006

CHMP recommends approval of Exelon for Parkinson's disease dementia

Feb. 8, 2006

Bicifadine studied in new phase II trial for diabetic peripheral neuropathy

Feb. 8, 2006

Research collaboration to evaluate nasal delivery for Alzheimer's disease

Feb. 8, 2006

Phase I study of EVT-101 completes single ascending dose component

Feb. 8, 2006

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...